Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2018

Open Access 01-12-2018 | Research

Dynamic development of metabolic syndrome and its risk prediction in Chinese population: a longitudinal study using Markov model

Authors: Xiaoxian Jia, Qicai Chen, Peipei Wu, Meng Liu, Xiaoxiao Chen, Juan Xiao, Lili Chen, Pengpeng Zhang, Shumei Wang

Published in: Diabetology & Metabolic Syndrome | Issue 1/2018

Login to get access

Abstract

Background

With the increasing prevalence of metabolic syndrome (MS), there is a need to track and predict the development of MS. In this study, we established a Markov model to explore the natural history and predict the risk of MS.

Methods

A total of 21,777 Chinese individuals who had at least two consecutive health check-ups between 2010 and 2015 were studied. MS was defined using the Chinese Diabetes Society criteria. Twelve metabolic abnormal states (the no component state, four isolated component states, six 2-component states, and the MS state) were contained in each Markov chain. The transition probability was the mean of five probabilities for the transition between any two states in 2 consecutive years.

Results

The dyslipidemia or overweight/obesity components were most likely to initiate the progress of MS in individuals aged 18–49. However, for individuals over 50 years old, the most likely initiating component of MS was dyslipidemia or hypertension. People who initially had dyslipidemia were most likely to develop the combined state of dyslipidemia with overweight/obesity before the age of 50, but after 50 years of age, the state of dyslipidemia merged with hypertension was the most common. Subjects (with the exception of males over 50 years of age who initially had an isolated state of hyperglycemia) who initially had an isolated state of overweight/obesity, hypertension, or hyperglycemia were most likely to develop a combination of one of these initial states with dyslipidemia. Males who initially had isolated hyperglycemia tended to develop hypertension after age 50. There was a greater chance for subjects who initially had an isolated hyperglycemia state or 2-component state that contained hyperglycemia to develop MS within 10 years compared to those who initially had other abnormal metabolic states.

Conclusions

The occurrence of MS primarily began with overweight/obesity or dyslipidemia in people aged 18–49. However, for those over 50 years old, MS primarily initiated under the conditions of dyslipidemia or hypertension. When MS started under the conditions of overweight/obesity, hypertension or hyperglycemia, dyslipidemia tended to occur next. People who initially had isolated hyperglycemia or a 2-component state that contained hyperglycemia had a higher risk of developing MS than those with other initiating states.
Literature
1.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.CrossRefPubMed Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.CrossRefPubMed
3.
go back to reference Liu M, Wang J, Jiang B, Sun D, Wu L, Yang S, Wang Y, Li X, He Y. Increasing prevalence of metabolic syndrome in a Chinese elderly population: 2001–2010. PLoS ONE. 2013;8(6):e66233.CrossRefPubMedPubMedCentral Liu M, Wang J, Jiang B, Sun D, Wu L, Yang S, Wang Y, Li X, He Y. Increasing prevalence of metabolic syndrome in a Chinese elderly population: 2001–2010. PLoS ONE. 2013;8(6):e66233.CrossRefPubMedPubMedCentral
4.
go back to reference Tran BT, Jeong BY, Oh J-K. The prevalence trend of metabolic syndrome and its components and risk factors in Korean adults: results from the Korean National Health and Nutrition Examination Survey 2008–2013. BMC Public Health. 2017;17(1):71.CrossRefPubMedPubMedCentral Tran BT, Jeong BY, Oh J-K. The prevalence trend of metabolic syndrome and its components and risk factors in Korean adults: results from the Korean National Health and Nutrition Examination Survey 2008–2013. BMC Public Health. 2017;17(1):71.CrossRefPubMedPubMedCentral
5.
go back to reference Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA. 2015;313(19):1973–4.CrossRefPubMed Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA. 2015;313(19):1973–4.CrossRefPubMed
6.
go back to reference Slagter SN, van Waateringe RP, van Beek AP, van der Klauw MM, Wolffenbuttel BHR, van Vliet-Ostaptchouk JV. Sex, BMI and age differences in metabolic syndrome: the Dutch Lifelines Cohort Study. Endocr Connect. 2017;6(4):278–88.CrossRefPubMedPubMedCentral Slagter SN, van Waateringe RP, van Beek AP, van der Klauw MM, Wolffenbuttel BHR, van Vliet-Ostaptchouk JV. Sex, BMI and age differences in metabolic syndrome: the Dutch Lifelines Cohort Study. Endocr Connect. 2017;6(4):278–88.CrossRefPubMedPubMedCentral
7.
go back to reference Riediger ND, Clara I. Prevalence of metabolic syndrome in the Canadian adult population. CMAJ. 2011;183(15):1127–34.CrossRef Riediger ND, Clara I. Prevalence of metabolic syndrome in the Canadian adult population. CMAJ. 2011;183(15):1127–34.CrossRef
8.
go back to reference Carnethon MR, Loria CM, Hill JO, Sidney S, Savage PJ, Liu K. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985–2001. Diabetes Care. 2004;27(11):2707–15.CrossRefPubMed Carnethon MR, Loria CM, Hill JO, Sidney S, Savage PJ, Liu K. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) study, 1985–2001. Diabetes Care. 2004;27(11):2707–15.CrossRefPubMed
9.
go back to reference Zuo H, Shi Z, Hu X, Wu M, Guo Z, Hussain A. Prevalence of metabolic syndrome and factors associated with its components in Chinese adults. Metabolism. 2009;58(8):1102–8.CrossRefPubMed Zuo H, Shi Z, Hu X, Wu M, Guo Z, Hussain A. Prevalence of metabolic syndrome and factors associated with its components in Chinese adults. Metabolism. 2009;58(8):1102–8.CrossRefPubMed
10.
go back to reference Yin X, Sun Q, Zhang X, Lu Y, Sun C, Cui Y, Wang S. Serum 25(OH)D is inversely associated with metabolic syndrome risk profile among urban middle-aged Chinese population. Nutr J. 2012;11:68.CrossRefPubMedPubMedCentral Yin X, Sun Q, Zhang X, Lu Y, Sun C, Cui Y, Wang S. Serum 25(OH)D is inversely associated with metabolic syndrome risk profile among urban middle-aged Chinese population. Nutr J. 2012;11:68.CrossRefPubMedPubMedCentral
11.
go back to reference Lu YC, Wang CP, Yu TH, Tsai IT, Hung WC, Lu IC, Hsu CC, Tang WH, Houng JY, Chung FM, et al. Shift work is associated with metabolic syndrome in male steel workers-the role of resistin and WBC count-related metabolic derangements. Diabetol Metab Syndr. 2017;9:83.CrossRefPubMedPubMedCentral Lu YC, Wang CP, Yu TH, Tsai IT, Hung WC, Lu IC, Hsu CC, Tang WH, Houng JY, Chung FM, et al. Shift work is associated with metabolic syndrome in male steel workers-the role of resistin and WBC count-related metabolic derangements. Diabetol Metab Syndr. 2017;9:83.CrossRefPubMedPubMedCentral
12.
go back to reference Kazemi-Bajestani SM, Tayefi M, Ebrahimi M, Heidari-Bakavoli AR, Moohebati M, Parizadeh SM, Esmaeili H, Ferns GA, Ghayour-Mobarhan M. The prevalence of metabolic syndrome increases with serum high sensitivity C-reactive protein concentration in individuals without a history of cardiovascular disease: a report from a large Persian cohort. Ann Clin Biochem. 2017;54(6):644–8.PubMed Kazemi-Bajestani SM, Tayefi M, Ebrahimi M, Heidari-Bakavoli AR, Moohebati M, Parizadeh SM, Esmaeili H, Ferns GA, Ghayour-Mobarhan M. The prevalence of metabolic syndrome increases with serum high sensitivity C-reactive protein concentration in individuals without a history of cardiovascular disease: a report from a large Persian cohort. Ann Clin Biochem. 2017;54(6):644–8.PubMed
13.
go back to reference Choi SH, Yun KE, Choi HJ. Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults. Nutr Metab Cardiovasc Dis. 2013;23(1):31–7.CrossRefPubMed Choi SH, Yun KE, Choi HJ. Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults. Nutr Metab Cardiovasc Dis. 2013;23(1):31–7.CrossRefPubMed
14.
go back to reference Scuteri A, Morrell CH, Najjar SS, Muller D, Andres R, Ferrucci L, Lakatta EG. Longitudinal paths to the metabolic syndrome: can the incidence of the metabolic syndrome be predicted? The Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci. 2009;64(5):590–8.CrossRefPubMed Scuteri A, Morrell CH, Najjar SS, Muller D, Andres R, Ferrucci L, Lakatta EG. Longitudinal paths to the metabolic syndrome: can the incidence of the metabolic syndrome be predicted? The Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci. 2009;64(5):590–8.CrossRefPubMed
15.
go back to reference Cheung BM, Wat NM, Tam S, Thomas GN, Leung GM, Cheng CH, Woo J, Janus ED, Lau CP, Lam TH, et al. Components of the metabolic syndrome predictive of its development: a 6-year longitudinal study in Hong Kong Chinese. Clin Endocrinol. 2008;68(5):730–7.CrossRef Cheung BM, Wat NM, Tam S, Thomas GN, Leung GM, Cheng CH, Woo J, Janus ED, Lau CP, Lam TH, et al. Components of the metabolic syndrome predictive of its development: a 6-year longitudinal study in Hong Kong Chinese. Clin Endocrinol. 2008;68(5):730–7.CrossRef
16.
go back to reference Tao LX, Wang W, Zhu HP, Huo D, Zhou T, Pan L, Gao Q, Luo YX, Wu LJ, Li X, et al. Risk profiles for metabolic syndrome and its transition patterns for the elderly in Beijing, 1992–2009. Endocrine. 2014;47(1):161–8.CrossRefPubMed Tao LX, Wang W, Zhu HP, Huo D, Zhou T, Pan L, Gao Q, Luo YX, Wu LJ, Li X, et al. Risk profiles for metabolic syndrome and its transition patterns for the elderly in Beijing, 1992–2009. Endocrine. 2014;47(1):161–8.CrossRefPubMed
17.
go back to reference Wang X, Yang F, Bots ML, Guo WY, Zhao B, Hoes AW, Vaartjes I. Prevalence of the metabolic syndrome among employees in Northeast China. Chin Med J. 2015;128(15):1989–93.CrossRefPubMedPubMedCentral Wang X, Yang F, Bots ML, Guo WY, Zhao B, Hoes AW, Vaartjes I. Prevalence of the metabolic syndrome among employees in Northeast China. Chin Med J. 2015;128(15):1989–93.CrossRefPubMedPubMedCentral
18.
go back to reference Hwang LC, Bai CH, You SL, Sun CA, Chen CJ. Description and prediction of the development of metabolic syndrome: a longitudinal analysis using a markov model approach. PLoS ONE. 2013;8(6):e67436.CrossRefPubMedPubMedCentral Hwang LC, Bai CH, You SL, Sun CA, Chen CJ. Description and prediction of the development of metabolic syndrome: a longitudinal analysis using a markov model approach. PLoS ONE. 2013;8(6):e67436.CrossRefPubMedPubMedCentral
19.
go back to reference Chen X, Chen Q, Chen L, Zhang P, Xiao J, Wang S. Description and prediction of the development of metabolic syndrome in Dongying City: a longitudinal analysis using the Markov model. BMC Public Health. 2014;14:1033.CrossRefPubMedPubMedCentral Chen X, Chen Q, Chen L, Zhang P, Xiao J, Wang S. Description and prediction of the development of metabolic syndrome in Dongying City: a longitudinal analysis using the Markov model. BMC Public Health. 2014;14:1033.CrossRefPubMedPubMedCentral
20.
22.
go back to reference Kabat GC, Wu WY, Bea JW, Chen C, Qi L, Stefanick ML, Chlebowski RT, Lane DS, Wactawski-Wende J, Wassertheil-Smoller S, et al. Metabolic phenotypes of obesity: frequency, correlates and change over time in a cohort of postmenopausal women. Int J Obes. 2017;41(1):170–7.CrossRef Kabat GC, Wu WY, Bea JW, Chen C, Qi L, Stefanick ML, Chlebowski RT, Lane DS, Wactawski-Wende J, Wassertheil-Smoller S, et al. Metabolic phenotypes of obesity: frequency, correlates and change over time in a cohort of postmenopausal women. Int J Obes. 2017;41(1):170–7.CrossRef
23.
go back to reference Chao J, Zong M, Xu H, Yu Q, Jiang L, Li Y, Song L, Liu P. The long-term effect of community-based health management on the elderly with type 2 diabetes by the Markov modeling. Arch Gerontol Geriatr. 2014;59(2):353–9.CrossRefPubMed Chao J, Zong M, Xu H, Yu Q, Jiang L, Li Y, Song L, Liu P. The long-term effect of community-based health management on the elderly with type 2 diabetes by the Markov modeling. Arch Gerontol Geriatr. 2014;59(2):353–9.CrossRefPubMed
24.
go back to reference Haring R, Rosvall M, Volker U, Volzke H, Kroemer H, Nauck M, Wallaschofski H. A network-based approach to visualize prevalence and progression of metabolic syndrome components. PLoS ONE. 2012;7(6):e39461.CrossRefPubMedPubMedCentral Haring R, Rosvall M, Volker U, Volzke H, Kroemer H, Nauck M, Wallaschofski H. A network-based approach to visualize prevalence and progression of metabolic syndrome components. PLoS ONE. 2012;7(6):e39461.CrossRefPubMedPubMedCentral
25.
go back to reference Barcelo MA, Rodriguez-Poncelas A, Saez M, Coll-de-Tuero G. The dynamic behaviour of metabolic syndrome and its components in an eight-year population-based cohort from the Mediterranean. PLoS ONE. 2017;12(5):e0176665.CrossRefPubMedPubMedCentral Barcelo MA, Rodriguez-Poncelas A, Saez M, Coll-de-Tuero G. The dynamic behaviour of metabolic syndrome and its components in an eight-year population-based cohort from the Mediterranean. PLoS ONE. 2017;12(5):e0176665.CrossRefPubMedPubMedCentral
26.
27.
go back to reference Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 2002;32(suppl 3):14–23.CrossRefPubMed Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 2002;32(suppl 3):14–23.CrossRefPubMed
28.
go back to reference Sharma AM. Obesity and cardiovascular risk. Growth Hormon IGF Res. 2003;13:S10–7.CrossRef Sharma AM. Obesity and cardiovascular risk. Growth Hormon IGF Res. 2003;13:S10–7.CrossRef
29.
go back to reference Després J-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J Suppl. 2006;8(suppl B):B4–12.CrossRef Després J-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J Suppl. 2006;8(suppl B):B4–12.CrossRef
30.
go back to reference Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. Hypertension. 2009;54(1):11–8.CrossRefPubMed Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. Hypertension. 2009;54(1):11–8.CrossRefPubMed
31.
go back to reference Wang L, Szklo M, Folsom AR, Cook NR, Gapstur SM, Ouyang P. Endogenous sex hormones, blood pressure change, and risk of hypertension in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2012;224(1):228–34.CrossRefPubMedPubMedCentral Wang L, Szklo M, Folsom AR, Cook NR, Gapstur SM, Ouyang P. Endogenous sex hormones, blood pressure change, and risk of hypertension in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2012;224(1):228–34.CrossRefPubMedPubMedCentral
32.
go back to reference McEniery CM, Wilkinson IB, Avolio AP. Age, hypertension and arterial function. Clin Exp Pharmacol Physiol. 2007;34(7):665–71.CrossRefPubMed McEniery CM, Wilkinson IB, Avolio AP. Age, hypertension and arterial function. Clin Exp Pharmacol Physiol. 2007;34(7):665–71.CrossRefPubMed
33.
go back to reference Sun GZ, Li Z, Guo L, Zhou Y, Yang HM, Sun YX. High prevalence of dyslipidemia and associated risk factors among rural Chinese adults. Lipids Health Dis. 2014;13:189.CrossRefPubMedPubMedCentral Sun GZ, Li Z, Guo L, Zhou Y, Yang HM, Sun YX. High prevalence of dyslipidemia and associated risk factors among rural Chinese adults. Lipids Health Dis. 2014;13:189.CrossRefPubMedPubMedCentral
34.
go back to reference Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Gaziano JM. Dyslipidemia and the risk of incident hypertension in men. Hypertension. 2006;47:45–50.CrossRefPubMed Halperin RO, Sesso HD, Ma J, Buring JE, Stampfer MJ, Gaziano JM. Dyslipidemia and the risk of incident hypertension in men. Hypertension. 2006;47:45–50.CrossRefPubMed
35.
go back to reference Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine. 2008;34(1–3):36–51.CrossRefPubMed Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine. 2008;34(1–3):36–51.CrossRefPubMed
36.
go back to reference Wang S, Xu L, Jonas JB, You QS, Wang YX, Yang H. Prevalence and associated factors of dyslipidemia in the adult Chinese population. PLoS ONE. 2011;6(3):e17326.CrossRefPubMedPubMedCentral Wang S, Xu L, Jonas JB, You QS, Wang YX, Yang H. Prevalence and associated factors of dyslipidemia in the adult Chinese population. PLoS ONE. 2011;6(3):e17326.CrossRefPubMedPubMedCentral
37.
go back to reference Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601–10.CrossRefPubMed Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601–10.CrossRefPubMed
38.
go back to reference DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–94.CrossRefPubMed DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–94.CrossRefPubMed
39.
go back to reference Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368(1–2):1–19.CrossRefPubMed Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368(1–2):1–19.CrossRefPubMed
40.
go back to reference Sowers JR, Khoury S, Standley P, Zemel P, Zemel M. Mechanisms of hypertension in diabetes. Am J Hypertens. 1991;4:177–82.CrossRefPubMed Sowers JR, Khoury S, Standley P, Zemel P, Zemel M. Mechanisms of hypertension in diabetes. Am J Hypertens. 1991;4:177–82.CrossRefPubMed
41.
go back to reference Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108(25):3097–101.CrossRefPubMed Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108(25):3097–101.CrossRefPubMed
42.
go back to reference Chedraui P, Escobar GS, Perez-Lopez FR, Palla G, Montt-Guevara M, Cecchi E, Genazzani AR, Simoncini T. Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome. Maturitas. 2014;77(4):370–4.CrossRefPubMed Chedraui P, Escobar GS, Perez-Lopez FR, Palla G, Montt-Guevara M, Cecchi E, Genazzani AR, Simoncini T. Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome. Maturitas. 2014;77(4):370–4.CrossRefPubMed
43.
go back to reference Jacobs MJ, Kleisli T, Pio JR, Malik S, L’Italien GJ, Chen RS, Wong ND. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005;70(3):263–9.CrossRefPubMed Jacobs MJ, Kleisli T, Pio JR, Malik S, L’Italien GJ, Chen RS, Wong ND. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005;70(3):263–9.CrossRefPubMed
44.
go back to reference Yu S, Yang H, Guo X, Zhang X, Zheng L, Sun Y. Prevalence of dyslipidemia and associated factors among the hypertensive population from rural Northeast China. BMC Public Health. 2015;15(1):1–9.CrossRef Yu S, Yang H, Guo X, Zhang X, Zheng L, Sun Y. Prevalence of dyslipidemia and associated factors among the hypertensive population from rural Northeast China. BMC Public Health. 2015;15(1):1–9.CrossRef
45.
go back to reference Schwarz PEH, Reimann M, Li J, Bergmann A, Licinio J, Wong ML, Bornstein SR. The metabolic syndrome—a global challenge for prevention. Horm Metab Res. 2007;39:777–80.CrossRefPubMed Schwarz PEH, Reimann M, Li J, Bergmann A, Licinio J, Wong ML, Bornstein SR. The metabolic syndrome—a global challenge for prevention. Horm Metab Res. 2007;39:777–80.CrossRefPubMed
46.
go back to reference Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.CrossRefPubMed Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113–32.CrossRefPubMed
47.
go back to reference Brown TM, Sanderson BK, Bittner V. Drugs are not enough: metabolic syndrome—a call for intensive therapeutic lifestyle change. J Cardiometab Syndr. 2009;4(1):20–5.CrossRefPubMedPubMedCentral Brown TM, Sanderson BK, Bittner V. Drugs are not enough: metabolic syndrome—a call for intensive therapeutic lifestyle change. J Cardiometab Syndr. 2009;4(1):20–5.CrossRefPubMedPubMedCentral
48.
go back to reference Lin YH, Chu LL. The health promotion lifestyle of metabolic syndrome individuals with a diet and exercise programme. Int J Nurs Pract. 2014;20(2):142.CrossRefPubMed Lin YH, Chu LL. The health promotion lifestyle of metabolic syndrome individuals with a diet and exercise programme. Int J Nurs Pract. 2014;20(2):142.CrossRefPubMed
49.
go back to reference Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program Randomized Trial. Ann Intern Med. 2005;142:611–9.CrossRefPubMedPubMedCentral Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program Randomized Trial. Ann Intern Med. 2005;142:611–9.CrossRefPubMedPubMedCentral
Metadata
Title
Dynamic development of metabolic syndrome and its risk prediction in Chinese population: a longitudinal study using Markov model
Authors
Xiaoxian Jia
Qicai Chen
Peipei Wu
Meng Liu
Xiaoxiao Chen
Juan Xiao
Lili Chen
Pengpeng Zhang
Shumei Wang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2018
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-018-0328-3

Other articles of this Issue 1/2018

Diabetology & Metabolic Syndrome 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.